Our Team

Only those who attempt the absurd can achieve the impossible.

Albert Einstein

Atakam Medical is a research company that develops bio-active compounds as candidates for creating novel therapies. We are an international team with a very strong scientific research and business background.

Andrew Osichnuk President

Successful entrepreneur from 1987. Founder and President of ATAKAM INC from 1990. Two master's degree: Philosophy (1982) and Applied mathematics in computer science (1997). Founder and vice president of Central European Bank (former).

Anatolii Demchenko Chief Scientific Officer

PhD in Chemistry (1986), Dr. Sc. Pharmacy (2001). Professor of the Department of Chemistry and Pharmacy. Graduated (1980) from Kiev State University as Chemistry Science. Anatolii is the author of 175 patents and more then 300 publications.

Eugene Stavtsev, MBA Chief Executive Officer

Gene Stavtsev is a seasoned biopharmaceutical executive with product launch and commercialization experience in Novartis and Amgen. Founded Anchor Bioresearch Dx focused on infectious diseases. Co-founded Atakam Medical with focus on antivirals, rare disease and cancer compounds. Holds MBA from Sawyer Business School and Master’s in Linguistics Kursk State University.

Dr. David E Gordon, PHD Chief of Virology

World-renowned virologist with a reputation for insightful experimental design and effective leadership. Working with the Krogan Lab and the QBI COVID-19 Research Group, he led the first study to map protein interactions between SARS-CoV-2 and human proteins, which was hailed as a landmark in COVID-19 research followed-up with studies of the other deadly coronaviruses SARS-CoV-1 and MERS.

Valery Polyakov, Ph.D. Corporate Attorney

Valery R. Polyakov, Ph.D., JD is an attorney admitted to practice law in California and USPTO. He has more than 20 year of industry experience in some of the largest pharma companies like Sanofi and Novartis as well as smaller biotechs. Valery is an accomplished inventor himself, having 19 granted patent and patent applications. He also has more than 30 published scientific papers in peer-reviewed journals. Valery co-invented a compound that is currently in phase II clinical trials for an oncological indication.

We use cookies to ensure you get the best experience on our website Ok
Atakam Inc. 1103 Old Town Ln, Suite 16, Cheyenne, WY 82009-4353